Ablaze Pharmaceuticals
PrivateLast Round
Series A
Nov 29, 2021
Total Funding Raised
$75M
Company Overview
Ablaze Pharmaceuticals operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series A round in November 2021.
Ablaze Pharmaceuticals is a biopharmaceutical company specializing in the development of Targeted Radiotherapy (TRT) treatments for cancer patients in the Chinese market.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ablaze Pharmaceuticals Comparables
Compare Ablaze Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AlphaGen Therapeutics | 89% | |
| C-Ray Therapeutics | 88% | |
| Yantai Lannacheng Biotechnology Co., Ltd. | 84% |
For institutional investors. Book with your work email.
Ablaze Pharmaceuticals Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Ablaze Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Nan Fung Life Sciences | Series A |
| Advantech Capital | Series A |
| Nan Fung Group | Series A |
| venBio | Series A |
| Venrock | Series A |
| Samsara BioCapital | Series A |
| Vivo Capital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 29, 2021
$75M round led by Vivo Capital and Advantech Capital.
For institutional investors. Book with your work email.
Ablaze Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ablaze Pharmaceuticals's valuation, stock price, and market status.
Is Ablaze Pharmaceuticals a public or private company?
Ablaze Pharmaceuticals is a private company.
What is the current stock price of Ablaze Pharmaceuticals?
Ablaze Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Ablaze Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ablaze Pharmaceuticals worth (valuation)?
Valuation information for Ablaze Pharmaceuticals is not publicly available.
Can I buy Ablaze Pharmaceuticals stock?
Ablaze Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ablaze Pharmaceuticals's last funding round?
Ablaze Pharmaceuticals's most recent funding round was Series A on November 29, 2021.
Who are the main investors in Ablaze Pharmaceuticals?
Key investors in Ablaze Pharmaceuticals include Advantech Capital, Vivo Capital.
Will Ablaze Pharmaceuticals IPO soon?
No public IPO plans have been announced for Ablaze Pharmaceuticals.
How can I track Ablaze Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Ablaze Pharmaceuticals's shares on secondary markets.